Skip to content
10-K

Annual Report

CANNAPHARMARX, INC. CPMD

0001654954-26-003108

← back to feed
Filed
Mar 31, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 31, 2026 678.5M sh
Shares Diluted FY 2025 · Dec 31, 2025 662.5M sh
Shares Diluted FY 2025 · Dec 31, 2024 625.28M sh
Capex FY 2025 · Dec 31, 2025 $5.52K
Capex FY 2025 · Dec 31, 2024 $0
Operating Cash Flow FY 2025 · Dec 31, 2025 −$789.1K
Operating Cash Flow FY 2025 · Dec 31, 2024 −$1.7M
Cash And Equivalents FY 2025 · Dec 31, 2025 $1.8K
Cash And Equivalents FY 2025 · Dec 31, 2024 $2.16K
Stockholders Equity FY 2025 · Dec 31, 2025 −$30.15M
Stockholders Equity FY 2025 · Dec 31, 2024 −$19.81M
Stockholders Equity FY 2025 · Dec 31, 2023 −$12.15M
Current Liabilities FY 2025 · Dec 31, 2025 $31.59M
Current Liabilities FY 2025 · Dec 31, 2024 $25.75M
Total Liabilities FY 2025 · Dec 31, 2025 $37.17M
Total Liabilities FY 2025 · Dec 31, 2024 $30.65M
Current Assets FY 2025 · Dec 31, 2025 $1.31M
Current Assets FY 2025 · Dec 31, 2024 $1.02M
Total Assets FY 2025 · Dec 31, 2025 $7.02M
Total Assets FY 2025 · Dec 31, 2024 $10.84M
Eps Diluted FY 2025 · Dec 31, 2025 −$0.02
Eps Diluted FY 2025 · Dec 31, 2024 −$0.02
Net Income FY 2025 · Dec 31, 2025 −$11.13M
Net Income FY 2025 · Dec 31, 2024 −$9.91M
Operating Income FY 2025 · Dec 31, 2025 −$3.35M
Operating Income restated FY 2025 · Dec 31, 2024 −$3.63M
Gross Profit FY 2025 · Dec 31, 2025 −$2.08M
Gross Profit FY 2025 · Dec 31, 2024 −$2.93M
Cost Of Revenue FY 2025 · Dec 31, 2025 $3.45M
Cost Of Revenue FY 2025 · Dec 31, 2024 $3.76M
Revenue FY 2025 · Dec 31, 2025 $1.36M
Revenue FY 2025 · Dec 31, 2024 $820.14K
Stock Repurchased FY 2025 · Mar 30, 2015 $350K